Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16035432 | 0.86 | KMT2A (0.39) | MAPTLMNATP53ACHELIMK1 | |
| SCHEMBL19616658 | 0.82 | TP53 (0.40) | MAPTKIF11LMNATP53ACHE | |
| SCHEMBL2797262 | 0.75 | MAPT (0.46) | MAPTLMNATP53CYP2C19 | |
| SCHEMBL19616868 | 0.73 | MAPT (0.40) | MAPTLMNATP53ACHECYP2C19 | |
| SCHEMBL22492620 | 0.72 | BRS3 (0.44) | LMNATP53CYP2C19MDM2 | |
| SCHEMBL16036328 | 0.71 | RAB9A (0.43) | MAPTACHECYP2C19SIGMAR1 | |
| SCHEMBL16035902 | 0.71 | RAB9A (0.43) | MAPTACHECYP2C19SIGMAR1 | |
| SCHEMBL16036331 | 0.71 | RAB9A (0.43) | MAPTACHECYP2C19SIGMAR1 | |
| SCHEMBL4976746 | 0.70 | SIGMAR1 (0.47) | TP53ACHELIMK1SIGMAR1 | |
| SCHEMBL4079977 | 0.69 | LIMK1 (0.49) | MAPTACHELIMK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| EP-3112366-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| EP-2970271-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-08 | — | — | EP | disclosed |
| US-20170174680-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| US-9604982-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-28 | — | — | US | disclosed |
| EP-3112366-A1 | P2X7 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2017-01-04 | — | — | EP | disclosed |
| US-20160024082-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | disclosed |
| US-9096596-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140275120-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | MAPT 3387/4885KIF11 3735/4885LMNA 1465/4885 |
| US-20140275120-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | MAPT 3481/4885KIF11 4216/4885LMNA 2581/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | MAPT 4185/4885KIF11 3913/4885LMNA 957/4885 |
| US-20160024082-A1 | P2X7 MODULATORS | P2RX1, P2RX5, P2RX3 | MAPT 205/4885KIF11 2049/4885LMNA 2104/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | MAPT 3387/4885KIF11 3735/4885LMNA 1465/4885 |
| US-20170174680-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | MAPT 3646/4885KIF11 4370/4885LMNA 2520/4885 |
| US-20180072724-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | MAPT 3646/4885KIF11 4370/4885LMNA 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.